Urology
Volume 75, Issue 3 , Pages 516-519 , March 2010

Post-transplantation Lymphoproliferative Disorder in the Renal Transplant Ureter

  • Mary K. Samplaski

      Affiliations

    • Glickman Urologic and Kidney Foundation, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Joshua Coleman

      Affiliations

    • Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio
    • ,
  • David Goldfarb

      Affiliations

    • Glickman Urologic and Kidney Foundation, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationReprint requests: David Goldfarb, M.D., Department of Urology and Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195

Received 2 September 2009 ,Accepted 26 October 2009.

References 

  1. Quigg RJ, Idelson BA, Greenfield A, et al. Transplant ureteral obstruction masquerading as recurrent rejection episodes: management by percutaneous antegrade balloon dilatation. Am J Kidney Dis. 1986;8:67–70
  2. Insall RL, Bell R, Hutchison BG, et al. A method for the treatment of ureteric complications following renal transplantation. Aust N Z J Surg. 1995;65:654–657
  3. Helling TS, Thomas CY, Moore JD, et al. The surgical approach to obstructive problems of the transplant ureter. Transplant Proc. 1982;14:751–760
  4. Lojanapiwat B, Mital D, Fallon L, et al. Management of ureteral stenosis after renal transplantation. J Am Coll Surg. 1994;179:21–24
  5. Senel MF, Van Buren CT, Riggs S, et al. Post-transplantation lymphoproliferative disorder in the renal transplant ureter. J Urol. 1996;155:2025
  6. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein–Barr virus: a distinct entity?. J Clin Oncol. 1998;16:2052–2059
  7. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990;323:1723–1728
  8. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8:984–989
  9. Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81:1227–1233
  10. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2003;4:222–230
  11. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein–Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med. 1996;154:1712–1717
  12. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein–Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant. 1995;14:214–221
  13. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant. 2002;6:396–399
  14. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076–1088
  15. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86:3333–3340

PII: S0090-4295(09)02849-0

doi: 10.1016/j.urology.2009.10.043

Urology
Volume 75, Issue 3 , Pages 516-519 , March 2010

Article Tools

* Image Usage & Resolution